Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III TrialPaul E. Goss, Lois E. Shepherd, James N. Ingle et al.|Journal of Clinical Oncology|2013Cited by 261
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01Aditya Bardia, Jennifer Friedmann, Noelia Martínez-Jáñez et al.|Journal of Clinical Oncology|2024Cited by 163
Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor TrialVered Stearns, Paul E. Goss, Judith‐Anne W. Chapman et al.|Journal of Clinical Oncology|2014Cited by 43